Valeant Plans New Sales Strategy For Cesamet; Ends Deal With Par
This article was originally published in The Pink Sheet Daily
Executive Summary
The two parties have terminated a marketing agreement for the anti-emetic based on a change in strategic priorities.
You may also be interested in...
Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Execs provide an update on plans for recharging Cesamet following a sluggish launch, and development plans for a new potential entry: retigabine for seizures.
Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Execs provide an update on plans for recharging Cesamet following a sluggish launch, and development plans for a new potential entry: retigabine for seizures.
Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus
Kadmus’ large-molecule approach dovetails with Organon’s small-molecule work to develop drug candidates based on fatty acid amide hydrolase technology, Organon exec David Nicholson tells “The Pink Sheet” DAILY.